{"url_path":"/sec/rntx/13dg/2026-05-08/000110465926057607","section_key":"body","section_title":"SCHEDULE 13G body","topic":"sec","document":{"doc_type":"SCHEDULE 13G","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1420565/0001104659-26-057607-index.html","accession_number":"0001104659-26-057607","cik":"0001420565","ticker":"RNTX","issuer_name":"Rein Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1420565/0001104659-26-057607-index.html","primary_entity_key":"0001420565","primary_entity_name":"Rein Therapeutics, Inc."},"word_count":116,"has_tables":true,"body_markdown":"EX-99.1\n2\ntm2613660d1_ex99-1.htm\nEXHIBIT 99.1\n\n**Exhibit 99.1**\n\n** **\n\n**JOINT FILING AGREEMENT**\n\nIn accordance with Rule 13d-1(k) under the Securities Exchange Act\nof 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including\namendments thereto) with respect to the Common Stock, par value $0.001 per share, of Rein Therapeutics, Inc., and further agree that\nthis Joint Filing Agreement be included as an Exhibit to such joint filing. In evidence thereof, the undersigned hereby execute this\nAgreement.\n\nDated: May 8, 2026\n\n**Lynwood Capital Management Inc.**\n\n**Lynwood Opportunities Master Fund**\n\n** **\n\nBy:\n/s/\nBenjamin Shapiro\n\nName:\nBenjamin Shapiro\n\nTitle:\nAuthorized Signatory\n\n/s/\nBenjamin Shapiro\n\nBenjamin Shapiro"}